Skip to main content

Table 4 Biodistribution results of [68Ga[Ga-DOTA-ST8950 at 1 and 2 h p.i. and [68Ga]Ga-DOTA-NOC at 1 h p.i

From: A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

[68Ga]Ga-DOTA-ST8950 [68Ga]Ga-DOTA-NOC
Organ 1 h# 2 h& 1 h (negative) 1 h&
Blood 1.9 ± 0.6 0.8 ± 0.2 1.5 ± 0.2 1.1 ± 0.4
Heart 1.3 ± 0.4 0.8 ± 0.2 1.1 ± 0.2 0.7 ± 0.2
Lung 5.4 ± 1.6 3.5 ± 0.7 4.6 ± 0.8 3.3 ± 1.4
Liver 6.4 ± 1.9 7.3 ± 1.5 6.2 ± 0.6 2.3 ± 0.7
Pancreas 8.5 ± 4.5 8.6 ± 2.1 7.4 ± 1.9 16 ± 3
Spleen 1.9 ± 0.6 1.5 ± 0.3 1.6 ± 0.1 0.8 ± 0.2
Stomach 7.5 ± 3.0 8.4 ± 1.2 6.0 ± 1.6 12 ± 2
Intestine 2.4 ± 1.3 2.7 ± 0.3 2.5 ± 0.2 3.3 ± 0.7
Adrenal 4.5 ± 0.9 4.3 ± 1.0 3.4 ± 0.7 4.6 ± 1.0
Kidney 14 ± 4 14 ± 2 12 ± 1 9.8 ± 3.2
Muscle 0.9 ± 0.3 0.6 ± 0.1 0.5 ± 0.1 0.5 ± 0.2
Femur 2.0 ± 0.6 2.4 ± 0.8 1.1 ± 0.1 1.7 ± 0.8
Pituitary 8.5 ± 1.9 7.8 ± 1.2 n.d. 8.2 ± 2.8
SST2 tumor 26 ± 8 32 ± 7 30 ± 8
SST5 tumor 15 ± 6 14 ± 3 12 ± 5
SST(-) tumor 1.4 ± 0.5
  1. Results are expressed as the mean of the % injected activity per gram of tissue (%IA/g) ± standard deviation (SD). The peptide mass and activity injected were 100 pmol and 2.5 MBq, for both radio-conjugates
  2. SST(-) somatostatin receptor negative
  3. #n = 8, &n = 5, n = 3, n.d. not determined